



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

GRIBBEN et al.

Application No: 10/732,847

Filed: December 9, 2003

For: *Methods of Inhibiting T Cell  
Proliferation or IL-2 Accumulation  
with CTLA-4 Specific Antibodies*

Art Unit: 1644

Examiner: Phillip Gambel

Attorney Docket No.: WYS-020.02

**CERTIFICATE OF FIRST-CLASS MAILING**

I hereby certify that this paper is being deposited with the United States Postal Service as First Class Mail, in an envelope addressed to: Mail Stop Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on December 21, 2006.

*Janann Ali*  
Janann Ali

Mail Stop Amendment  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

**RESPONSE TO RESTRICTION REQUIREMENT**

Sir:

This paper is being filed in response to the Restriction Requirement, mailed on September 21, 2006, in the above-referenced application. A petition for a two-month extension of time is submitted herewith. Applicants submit the following remarks in this Response.

Claims 1-14 are currently pending in the application. The Examiner has required multiple species elections under 35 U.S.C. §121.

The Examiner has required an election to a blocking molecule, which binds to a ligand selected from the group consisting of B7-1, B7-2, and CD28, as recited in claim 4. In response, Applicants elect, **with traverse, an anti-B7-2 antibody as the blocking molecule, for search purposes only**, to which prosecution on the merits shall be restricted if no generic claim is finally held allowable. Traversal is to the extent that no undue burden would be required to